WET AGE-RELATED MACULAR DEGENERATION
Clinical trials for WET AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Eye drop trial offers hope for wet AMD patients
Disease control OngoingThis early-stage study is testing whether NT-101 eye drops are safe and might help control wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults. The trial will enroll 30 participants aged 50+ who have active wet AMD in one eye. Researchers wi…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: NexThera Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for blurry vision: experimental drugs challenge standard eye treatment
Disease control OngoingThis study is testing two new eye injection medications against the current standard treatment for wet age-related macular degeneration, a leading cause of vision loss in older adults. Researchers want to see if the new drugs work as well or better at preserving eyesight over one…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
One-shot gene therapy aims to free patients from endless eye injections
Disease control OngoingThis study is observing the long-term safety and effectiveness of a one-time gene therapy injection for wet age-related macular degeneration (AMD), a leading cause of blindness. It follows 23 people for up to 10 years after they received the therapy in a previous trial. The goal …
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Potential game changer: eye implant could drastically reduce injections for blinding disease
Disease control OngoingThis study is testing if a new, long-acting eye implant (EYP-1901) can work as well as standard aflibercept injections for treating wet age-related macular degeneration (AMD), a leading cause of vision loss. It aims to see if the implant can maintain or improve vision while reduc…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Eye implant aims to free patients from frequent injections for blinding disease
Disease control OngoingThis study is testing whether a new, long-acting eye implant (EYP-1901) can work as well as the current standard treatment (aflibercept injections) for wet age-related macular degeneration (AMD). It will involve about 400 people who have this eye condition. The main goal is to se…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Could new eye injection schedule mean fewer shots for AMD patients?
Disease control OngoingThis study is testing whether two different eye injection drugs (aflibercept and brolucizumab) can effectively treat wet age-related macular degeneration with fewer injections from the start. Researchers want to see if patients can go longer between treatments without losing visi…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: Berner Augenklinik • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New home eye test could transform monitoring for blinding disease
Diagnosis OngoingThis study is testing a new automated eye-tracking system called AVIGA. It aims to help doctors monitor vision changes in people with wet age-related macular degeneration (AMD) more easily and objectively. The system tracks where a person looks to detect problems with central vis…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Sponsor: Tan Tock Seng Hospital • Aim: Diagnosis
Last updated Mar 30, 2026 14:27 UTC